Georgia’s 2025 Hope for Georgia Patients Act (SB 72) significantly broadened the state’s right-to-try framework, empowering terminally ill patients to access experimental drugs, biologics, devices, and gene therapies that lack full FDA approval. This expansion targets individuals exhausted by conventional treatments, offering a streamlined pathway while emphasizing informed consent, substantial risks, and financial hurdles. Building on the 2016 federal Right to Try Act, SB 72 reflects Georgia’s commitment to patient autonomy in end-of-life scenarios, though practical barriers persist.
Understanding Right-to-Try Laws
Right-to-try legislation allows patients facing imminent death to bypass certain FDA protocols for investigational therapies outside clinical trials. In Georgia, eligibility requires:
- Certification of a terminal illness by two physicians—one can be the treating doctor—defining it as an advanced condition likely causing death within 12 months despite standard care.
- Exhaustion of all approved treatment options.
- Inability to enroll in a suitable clinical trial due to location, health status, or availability.
Previously limited in scope, Georgia’s law now aligns with national trends seen in over 40 states, prioritizing hope over regulatory delays for those with no time left.
SB 72’s Major Expansions
The 2025 updates introduce practical enhancements:
- Broader therapy inclusion: Encompasses not only drugs but biologics, medical devices, and gene therapies that have completed Phase 2 clinical trials—demonstrating preliminary safety and efficacy—or earned FDA breakthrough therapy designation.
- Accelerated timelines: Manufacturers must respond to patient requests within 10 business days, down from lengthier processes elsewhere; they face no obligation to supply but gain civil liability immunity if they do.
- Bypassing federal red tape: Eliminates the need for FDA’s expanded-access IND application, which often takes months.
- Simplified physician involvement: Treating doctors can provide one certification, paired with a second opinion, easing administrative burdens.
These changes reduce barriers, enabling faster decisions in critical windows.
Eligibility Criteria and Step-by-Step Process
Qualification remains rigorous to protect vulnerable patients:
| Criterion | Details |
|---|---|
| Terminal Illness | Advanced, life-limiting within 12 months; dual physician certification required. |
| Treatment Status | FDA-investigational, post-Phase 2 or breakthrough-designated; unavailable in trials. |
| Patient Status | Exhausted approved therapies; no trial access. |
Access follows a clear sequence:
- Patient, family, or advocate submits a formal request to the therapy’s manufacturer.
- Two physicians submit written eligibility confirmations.
- Manufacturer voluntarily approves or denies (no forced provision).
- Patient executes detailed informed consent, acknowledging potential for severe side effects, disease acceleration, or zero benefit.
- Treatment proceeds under treating physician supervision, with mandatory FDA adverse-event reporting.
This structure balances access with accountability.
Real-World Benefits and Examples
SB 72 unlocks therapies at the innovation frontier:
- Cancer immunotherapies and CAR-T cell treatments for metastatic cases, where Phase 2 results show tumor shrinkage but full approval lags.
- Gene therapies for pediatric rare diseases like spinal muscular atrophy or certain leukemias, offering functional recovery in early data.
- Emerging biologics for neurodegenerative conditions such as ALS or Alzheimer’s, providing novel mechanisms when options dwindle.
Advocates point to heartening cases—like a Georgia child with rare sarcoma gaining a year of quality life via experimental access—arguing that paperwork should not doom the dying. Nationally, while federal right-to-try activations numbered under 300 annually pre-2025, state expansions like Georgia’s amplify reach.
Critical Risks and Limitations
The law mandates warnings of downsides:
- Efficacy and safety unknowns: Phase 2 evidence is nascent; therapies may exacerbate illness, trigger toxicities, or fail entirely.
- Prohibitive costs: No coverage from insurance, Medicare, or Medicaid; out-of-pocket expenses range from tens of thousands to over $500,000 per course, set unilaterally by manufacturers.
- Uncertain availability: Companies may prioritize trials or profitability, denying requests without recourse.
- Oversight gaps: Lacking full FDA IND scrutiny, monitoring is minimal, risking complications in palliative transitions.
Ethical critiques highlight potential trial sabotage or financial exploitation of grief-stricken families.
Actionable Guidance for Patients and Families
Navigating SB 72 demands preparation:
- Engage oncology, neurology, or palliative specialists immediately to pinpoint Phase 2 candidates and secure certifications.
- Leverage ClinicalTrials.gov to identify manufacturers, then submit precise requests with medical records.
- Explore patient assistance foundations, compassionate-use programs, or crowdfunding for costs.
- Maintain meticulous documentation of all communications, consents, and outcomes for legal or reimbursement purposes.
- Integrate with hospice discussions, weighing experimental unknowns against comfort-focused care.
Physicians bear responsibility for comprehensive consent counseling.
Federal Alignment and Clinical Trial Context
SB 72 harmonizes with federal law without supplanting FDA manufacturing, shipping, or pharmacovigilance rules. It serves trial-ineligible patients—those barred by geography, comorbidities, or slots—while feeding real-world data into approval pipelines. Clinical trials remain the gold standard for rigorous validation.
Policy Drivers and Future Directions
Georgia’s reforms respond to advocacy amid opioid and chronic disease burdens, potentially extending to addiction reversal agents. Low uptake historically underscores rarity, but viral success stories propel momentum. Prospects include cost subsidies or Phase 1 inclusions, though trial-funding skeptics urge caution.
Essential Takeaway
SB 72 equips terminally ill Georgians with a vital, expedited route to Phase 2 innovations when clocks tick down. It champions choice amid despair but necessitates sober evaluation of steep risks, expenses, and probabilities. Pair it with trials, palliation, and counsel—act decisively, as every moment matters.
Disclaimer
The information provided on this blog is for general informational purposes only and is
not intended to serve as legal advice. While I am a paralegal, I am not a licensed attorney, and the content shared here should not be construed as such.
No attorney-client relationship is formed through the use of this blog or by any communication with me. For specific legal advice tailored to your situation, please consult with a qualified attorney who is licensed to practice law in your jurisdiction.
I strive to ensure that the information presented is accurate and up-to-date; however, I make no representations or warranties regarding the completeness, accuracy, reliability, suitability, or availability of any information contained on this blog. Any reliance you place on such information is strictly at your own risk.
Thank you for visiting my blog, and please feel free to reach out with any questions or comments!